- BySeeking Alpha-
Shattuck Labs (NASDAQ:STTK): Q1 GAAP EPS of -$0.28 beats by $0.11.Revenue of $2.27M (-23.8% Y/Y) beats by $0.29M.Press Release
AUSTIN, TX and DURHAM, NC, April 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
Shares of Shattuck Labs, Inc. (STTK) have declined sharply so far this year, with losses hovering around 43%. However, STTK might present an unmissable opportunity, as some...
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of dual-sided fusion proteins. The Company has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The Company's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.